Medigene Announces Results from Investigator Initiated Trial of EndoTAG®-1 to be Published for ASCO 2013
April 11 2013 - 1:30AM
Medigene AG / Medigene Announces Results from Investigator
Initiated Trial of EndoTAG®-1 to be Published for ASCO 2013 .
Processed and transmitted by Thomson Reuters ONE. The issuer is
solely responsible for the content of this announcement.
Martinsried/Munich, April 11,
2013. Medigene AG (Frankfurt, Prime Standard; MDG) announced
today that the results from the Phase 2 investigator initiated
trial (IIT) of EndoTAG®-1 in
HER2-negative breast cancer will be published for the upcoming
Annual Meeting of the American Society of Clinical Oncology (ASCO).
The abstract (#114428), entitled "Feasibility study of cationic
liposome-encapsulated paclitaxel in combination with paclitaxel
followed by FEC as induction therapy in HER2-negative breast
cancer" was chosen for inclusion online in the ASCO 2013 Annual
Meeting Proceedings, a Journal of Clinical Oncology supplement, and
will be released at www.asco.org on May 15, 2013.
The investigator initiated trial
with EndoTAG®-1 was
conducted by Prof. Dr. Ahmad Awada, Head of the Medical Oncology
Clinic at the Institut Jules Bordet in Brussels, Belgium, and
principal investigator in the previously conducted
EndoTAG®-1 phase II
trial in locally relapsed and/or metastatic advanced Triple
Negative Breast Cancer (TNBC). The aim of the exploratory
open-label Phase 2 IIT was to evaluate the efficacy and safety of
neoadjuvant EndoTAG®-1 in
combination with paclitaxel in patients with HER2-negative breast
cancer.
About
EndoTAG®-1: EndoTAG®-1 is a novel
composition of the established cytostatic drug paclitaxel combined
with neutral and positive lipids. The positively charged lipids
imply that EndoTAG®-1 interacts
with newly developed, negatively charged endothelial cells, which
are primarily required for the growth of tumor blood vessels. The
EndoTAG®-1 paclitaxel
component attacks the endothelial cells as they divide, thus
targeting the blood supply to tumors without affecting the supply
to healthy tissue. By doing this, EndoTAG®-1 is expected
to prevent the formation of new tumor blood vessels and to inhibit
tumor growth. Medigene has successfully completed two clinical
phase II trials of EndoTAG®-1 in the
indications pancreatic cancer and triple-negative breast cancer
(TNBC).
Medigene AG
(Frankfurt: MDG, prime standard) is a publicly listed biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene
focuses on clinical research and development of novel drugs against
cancer and autoimmune diseases. Medigene is the first German
biotech company to have revenues from a marketed product
(Veregen®), which is
distributed by partner companies. Medigene has two drug candidates
in clinical trials, EndoTAG®-1 and
RhuDex®, and is
developing an innovative vaccine technology. For more information,
please visit www.medigene.com.
This press release contains
forward-looking statements representing the opinion of Medigene as
of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of
these forward-looking statements. Medigene® and Veregen® are registered trademarks of
Medigene AG. Polyphenon E® is a trademark of Mitsui Norin
Co., Ltd. These trademarks may be owned or licensed in select
locations only.
Contact
Julia Hofmann, Claudia
Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
To unsubscribe from the press
release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF
This
announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the
information contained therein.
Source: Medigene AG via Thomson Reuters ONE
HUG#1692200
Meridian Gold (NYSE:MDG)
Historical Stock Chart
From Dec 2024 to Jan 2025
Meridian Gold (NYSE:MDG)
Historical Stock Chart
From Jan 2024 to Jan 2025
